3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lymphatic Metastasis
1
Gestational Trophoblastic Neoplasias (GTN)
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Advanced Solid Tumor
1
Interventions
Injections
6
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Bevacizumab
4
toripalimab
3
fludarabine
2
Specimen Handling
2
Nivolumab
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
donafenib
1
disitamab vedotin
1
dabrafenib
1
cemiplimab
1
avelumab
1
atezolizumab
1
anlotinib
1
WW Domain-Containing Oxidoreductase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Solid Tumor
×
avelumab
×
Clear all
NCT03707808
2025-01-20
myDAvIpNi
Universitair Ziekenhuis Brussel
Phase 1/2
Recruiting
18 enrolled